Global Research

EQS-News: Lenzing honours early stage researchers with the Young Scientist Award

Retrieved on:

Friday, May 3, 2024

Textile, Congress, Dornbirn, GFC, Thought, EUR, Research, Student, Young Scientist Award, Recycling, Lenzing AG, Global Research

The application deadline is 30 June 2024 and the winning project will receive prize money of EUR 5,000.

Key Points:

The application deadline is 30 June 2024 and the winning project will receive prize money of EUR 5,000.
For the third time, the Lenzing Group is honouring young researchers with the Lenzing Young Scientist Award for excellent research work in the field of fibers and textiles.
“Lenzing has been an innovation leader in sustainably produced cellulose fibers for decades and is therefore at the forefront of change.
Applicants for the Young Scientist Award have the opportunity to submit their work (theses, papers, etc.)

AIG Appoints Kelly Lafnitzegger Executive Vice President and Chief Human Resources & Diversity Officer

Retrieved on:

Monday, April 29, 2024

Professional Services, Insurance, Human Resources, Learning, Transport, General Electric, American International Group, Acquisition, AIG, CHRO, International Marxist Group, Multimedia, Diversity, Global Research, Management

American International Group, Inc. (NYSE: AIG) today announced that Kelly Lafnitzegger will join AIG as Executive Vice President and Chief Human Resources & Diversity Officer (CHRO), effective June 1, 2024.

Key Points:

American International Group, Inc. (NYSE: AIG) today announced that Kelly Lafnitzegger will join AIG as Executive Vice President and Chief Human Resources & Diversity Officer (CHRO), effective June 1, 2024.
Ms. Lafnitzegger will report to Peter Zaffino, AIG Chairman & Chief Executive Officer, and will be a part of AIG’s Executive Leadership Team.
Previously, Ms. Lafnitzegger held a series of human resources leadership roles in GE’s Corporate, Capital, Healthcare, Global Research, Transportation and Power divisions.
Ms. Lafnitzegger succeeds Rose Marie Glazer, who has served as AIG’s Chief Human Resources & Diversity Officer since January 1, 2022, and has transitioned to AIG’s General Counsel.

Kaspersky report shows just how common scams are becoming on popular apps and websites

Retrieved on:

Thursday, April 25, 2024

Privacy, Digital, Internet, Kaspersky Lab, Social media, Artificial intelligence, Global Research, AI, Online shopping

WOBURN, Mass., April 25, 2024 /PRNewswire/ -- Kaspersky has released a new survey report, "Digital Uncertainty: Scams, Privacy and Artificial Intelligence," revealing that users are frequently encountering scams on social media, dating apps, gaming platforms, banking and sports betting sites. Among the top findings were that 42% of users have encountered scams on online dating apps, 38% have encountered scams on Facebook and even 18% of users of online sports betting sites. Overall, 29% of users have actually fallen victim to some type of scam on one of these online platforms.

Key Points:

Among the top findings were that 42% of users have encountered scams on online dating apps, 38% have encountered scams on Facebook and even 18% of users of online sports betting sites.
Kaspersky data shows that one of the most common forms of scam – phishing attacks – grew by 40% in 2023.
The survey found that 36% of Facebook Marketplace users have encountered scams on the platform, where scams can take various forms.
Twenty-five percent of Instagram users have encountered scams on the app, followed by online gaming platforms (18% of users encountered scams), and online banking (15%).

NVIDIA Powers Japan’s ABCI-Q Supercomputer for Quantum Research

Retrieved on:

Monday, March 18, 2024

ABCI, AIST, Development, Algorithm, Deep learning super sampling, H100, Global Research, Business, InfiniBand, SAN, Research, Fujitsu, Biology, Machine learning, NVIDIA, Microscope

SAN JOSE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- GTC—NVIDIA today announced that Japan’s new ABCI-Q supercomputer — designed to advance the nation’s quantum computing initiative — will be powered by NVIDIA platforms for accelerated and quantum computing.

Key Points:

SAN JOSE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- GTC—NVIDIA today announced that Japan’s new ABCI-Q supercomputer — designed to advance the nation’s quantum computing initiative — will be powered by NVIDIA platforms for accelerated and quantum computing.
The high-performance, scalable system is integrated with NVIDIA® CUDA-Q ™, an open-source hybrid quantum computing platform with powerful simulation tools and capabilities to program hybrid quantum-classical systems.
“Researchers need high-performance simulation to tackle the most difficult problems in quantum computing,” said Tim Costa, director of high performance computing and quantum computing at NVIDIA.
“The NVIDIA CUDA-Q platform and NVIDIA H100 will help these scientists pursue the next frontiers of quantum computing research.”
ABCI-Q is part of Japan’s quantum technology innovation strategy, which aims to create new opportunities for businesses and society to benefit from quantum technology, including through research in AI, energy and biology.

Vertex to Participate in Upcoming Investor Conferences

Retrieved on:

Tuesday, February 20, 2024

Biotechnology, Pharmaceutical, Genetics, Health, VRTX, News, Conference, Global Research, Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences:

Key Points:

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences:
TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 a.m.
Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 4:00 p.m.
A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page.
A replay of the conference webcast will be archived on the company's website.

Alliance One Positions Business for Growth in International Seed Sector

Retrieved on:

Thursday, January 18, 2024

Development, Seed, Nutrient, Research, Farmer, Culture, Global Research, Pyxus International, Genetics, Sale, Tobacco, Disease resistance, Agriculture

MORRISVILLE, N.C., Jan. 18, 2024 /PRNewswire/ -- Alliance One International, LLC ("Alliance One") is pleased to announce the recent opening of its seed industrialization unit, the latest investment in its Global Research, Development and Deployment Center in Passo do Sobrado, Brazil.

Key Points:

MORRISVILLE, N.C., Jan. 18, 2024 /PRNewswire/ -- Alliance One International, LLC ("Alliance One") is pleased to announce the recent opening of its seed industrialization unit, the latest investment in its Global Research, Development and Deployment Center in Passo do Sobrado, Brazil.
Alliance One is the leading supplier in Brazil's tobacco seed market, with tobacco grown from the Company's varieties comprising approximately 40 percent of the tobacco produced in the country.
The installation of its new, state-of-the-art seed industrialization unit positions the Company for global growth as a leader in tobacco crop solutions with the ability to provide customers and farmers with best-in-class genetics.
"Improved quality control opens doors to sell our seed in new markets at a faster speed, increases customer and farmer satisfaction, and drives efficiencies within our business."

Kaspersky survey: 71% of drivers would buy a car with less tech to protect their privacy

Retrieved on:

Thursday, January 11, 2024

Kaspersky Lab, Privacy, Research, CarPlay, Marital status, Policy, Insurance, Global Research, Data collection, Risk, Computer, Bluetooth, Safety, Apple, Mozilla, Android Auto

WOBURN, Mass., Jan. 11, 2024 /PRNewswire/ -- Kaspersky has released a new survey report showing that 72 percent of drivers are uncomfortable with the idea of automakers sharing their data with third parties. The report, "Is my car spying on me?" captures drivers' thoughts about automakers' use of personal data gleaned from connected cars. Eighty-seven percent of survey participants said automakers should be required to delete their data upon request, and only 28% said they have some idea what kind of data their car collects.

Key Points:

Some car manufacturers are even setting up subscription services , based on in-car tech features, to create new, multi-billion dollar lines of revenue.
To find out more about drivers' level of awareness and concern about these issues, Kaspersky surveyed 2,000 U.S. drivers in November 2023.
Strikingly, 71% of drivers even said they would consider buying an older car or one with less technology, in order to protect their privacy and security.
Buy an older car or a car with a minimal set of "smart" sensors and/or no communication module.

ConcertAI and Caris Life Sciences Announce Strategic Agreement with AbbVie to Accelerate Oncology Pipeline and Clinical Trials

Retrieved on:

Tuesday, January 9, 2024

Big data, Artificial intelligence, Machine learning, Patient, Research, Collection, Partnership, Global Research, Cancer, Drug discovery, Drug development, AbbVie, Clinical trial, Medicine, SVP, Pharmaceutical industry

CAMBRIDGE, Ma. and IRVING, Texas, Jan. 9, 2024 /PRNewswire/ -- ConcertAI and Caris Life Sciences (Caris) announced a multi-year partnership to support AbbVie's precision medicine-driven research and development efforts, and clinical trial optimization in oncology.

Key Points:

Agreement enables AbbVie to leverage ConcertAI and Caris' extensive clinical and genomic databases, coupled with Artificial Intelligence and Machine Learning (AI/ML)-derived insights to accelerate drug discovery, clinical development and precision medicine efforts in oncology
CAMBRIDGE, Ma.
and IRVING, Texas, Jan. 9, 2024 /PRNewswire/ -- ConcertAI and Caris Life Sciences (Caris) announced a multi-year partnership to support AbbVie's precision medicine-driven research and development efforts, and clinical trial optimization in oncology.
The agreement will also allow AbbVie to utilize ConcertAI and Caris' clinical network and laboratory capabilities combined with AI/ ML learning to optimize oncology clinical trials and patient enrollment.
"This work may help identify novel targets and mechanisms, and key levers to drive clinical trial excellence to support AbbVie's oncology portfolio."

Barclays appoints Ryan Voegeli as Head of Investment Banking for Canada

Retrieved on:

Thursday, January 4, 2024

Barclays today announces the appointment of Ryan Voegeli as Head of Investment Banking for Canada.

Key Points:

Barclays today announces the appointment of Ryan Voegeli as Head of Investment Banking for Canada.
Mr. Voegeli has twenty years of investment banking experience, and joins Barclays from CIBC Capital Markets where he was Head of Global Diversified Industries Investment Banking.
Prior to joining CIBC in 2011, Mr. Voegeli was Head of Canadian Telecom, Media & Technology Investment Banking at Bank of America Merrill Lynch.
The Barclays Canada team delivers Investment Banking, Global Markets, and Global Research coverage, providing clients in Canada with seamless access to Barclays’ global network, and extensive in-country opportunities for international clients.

Vertex to Present at Upcoming Investor Conferences

Retrieved on:

Thursday, October 26, 2023

Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Vertex Pharmaceuticals, News, Global Research, Conference, New Çeltek events, VRTX, Management, Vertex

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.

Key Points:

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in a fireside chat at UBS Biopharma Conference on Thursday, November 9, 2023 at 12:00 p.m.
Stuart Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 8:30 a.m. GMT.
A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page.